Business
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET.
About this update from Adc Therapeutics Sa
[{"type":"text","content":"LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET.","length":278,"tagName":"p"},{"type":"image","alt":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","displaySize":"","headline":null,"caption":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":250,"url":"https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xnw4DzeStakBHZIZhIV_hA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ0MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7","width":400,"height":250}},"href":"https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.","length":244,"tagName":"p"},{"type":"text","content":"About ADC Therapeutics","length":22,"tagName":"p"},{"type":"text","content":"ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.","length":279,"tagName":"p"},{"type":"text","content":"ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.","length":499,"tagName":"p"},{"type":"text","content":"ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has o...